Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin

Experimental and Clinical Endocrinology and Diabetes

Volumn 107, Issue 6, 1999, Pages 379-385

  Sillem, M ^b   Parviz, M ^b   Woitge, H W ^b   Kiesel, L ^b   Ulrich, U ^b   Von Holst, Th ^b   Runnebaum, B ^b   Ziegler, R ^b   Seibel, Markus J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

Bone loss; Bone turnover; GnRH analogue; Medrogestone; Progestins

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; DEOXYPYRIDINOLINE; GESTAGEN; GOSERELIN; HYPOTHALAMUS RELEASING FACTOR; MEDROGESTONE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUMBAR SPINE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032884411     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1212129     Document Type: Article

References (37)

1. Black D, Duncan A, Robins SP: Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversephase high-performance liquid chromato-graphy. Anal Biochem 169: 197-203, 1988
2. Cedars MI, Lu JKH, Meldrum D, Judd HL: Treatment of endometriosis with a long-acting gonadotropin releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 75: 641-645, 1990
3. Chesnut CH 3rd, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ: Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predict response of bone mineral density. Am J Med 102: 29-37, 1997
4. Compston JE, Yamaguchi K, Croucher PI, Garrahan NJ, Lindsay PC Shaw RW: The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 16/2: 261-267, 1995
5. Cundy T, Farquhar CM, Cornish J, Reid I: Short term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women. J Clin Endocrinol Metab 81: 1014-1017, 1996
6. Dawood MY: Impact of medical treatment of endometriosis on bone mass. Am J Obstet Gynecol 168: 674-684, 1993
7. Dlugi AM, Miller JD, Knittle J, Lupron Study Group: Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 54/3: 419-427, 1990
8. Erlik Y, Meldrum DR, Lagasse LD, Judd HL: Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women. Maturitas 3/2: 167-172, 1981
9. Fogelman I: Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 57/4: 715-724, 1992
10. Garnero P, Delmas PD: Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77: 1046-1053, 1993
11. Henderson AF, Studd JWW: The role of definitive surgery and hormone replacement therapy in the treatment of endometriosis. In: Thomas EJ, Rock JA (eds.). Modern approaches to endometriosis. First Edition, pp 275-289. Kluwer Academic Press, Dordrecht, 1991
12. Howell R, Edmonds DK, Dowsett M, Crook D, Lees B, Stevenson JC: Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 64/3: 474-481
13. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C: The effect of a gonadotropin-releasing hormone agonist (Nafarelin) on bone metabolism. J Clin Endocrinol Metab 67: 701-706, 1988
14. Kiilholma P, Tuimala R, Kivinen S, Korhonen M, Hagman E: Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 64/5: 903-908, 1995
15. Klehr-Bathmann I, Kuhl H: Formation of ethinylestradiol in post-menopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas 21: 245-250, 1995
16. Kontula K, Paavonen T, Luukainen T, Andersson LC: Binding of progestin s to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 32/9: 1511-1518, 1983
17. Lemay A, Surrey ES, Friedman AJ: Extending the use of gonadotropin-releasing hormone agonists: the emerging role of steroidal and nonsteroidal agents. Fertil Steril 61/1: 21-34, 1994
18. Lian J, Grundberg C: Basic science and pathology. Osteocalcin: biochemical considerations and clinical applications. Clin Orthop 226: 267-291, 1988
19. Naessen T, Olsson SE, Gudmundson J: Differential effects of progestogen-only methods for contraception in premenopausal women. Contraception 52/1: 35-39, 1995
20. Newhall-Perry K, Holloway L, Osburn L, Monroe SE, Heinrichs L, Hennzl M, Marcus R: Effects of a gonadotropin releasing hormone agonist on the calcium-parathyroid axis and bone turn-over in women with endometriosis. Am J Obstet Gynecol 173: 824-829, 1995
21. Pratt DA, Daniloff Y, Duncan A, Robins SP: Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem 207: 16-175, 1992
22. Prior JC: Progesterone as a bone-trophic hormone. Endocrine Rev 11/2: 386-398, 1990
23. Prior JC: Progesterone and ist role in bone remodelling. In: Ziegler R, Pfeilschifter J, Bräutigam M (eds.). Sex steroids and bone. Ernst Schering research foundation workshop 9. pp 29-56. Springer, Berlin, Heidelberg, New York, 1993
24. Prior JC, Vigna YM, Wark JD, Eyre DR, Lentle BC, Li DKB, Ebeling PR, Alley L: Premenopausal ovariectomy-related bone loss. A randomized double-blind one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 12: 1851-1863, 1997
25. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP: The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72/2: 382-386, 1991
26. Riis BJ, Christiansen C, Johansen JS, Jacobson J: Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metabol 70: 920-924, 1990
27. Robins SP, Duncan A, Wilson N, Evans BJ: Standardization of pyridinium crosslinks, pyridinoline and desoxypyridinoline, for use of biochemical markers of collagen degradation. Clin Chemistry 42: 1621-1626, 1996
28. Scharla SH, Minne HW, Waibel-Treber S, Schaible A, Lempert UG, Wüster C, Leyendecker G, Ziegler R: Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 70: 1055-1061, 1990
29. Seibel MJ, Baylink F, Farley JR, Epstein S, Yamauchi M, Eastell R, Pols HA, Raisz LG. Gundberg CM: Basic sciene and clinical application of bone biomarkers. Exp Clin Endocrinol Diabetes 105: 125-133, 1997
30. Seibel MJ, Cosman V, Shen V, Ratcliffe A, Lindsay R: Urinary hydroxy-pyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Min Res 8/7: 881-889, 1993
31. Seibel MJ, Duncan A, Robins SP: Urinary hydroxy-pyridinium crosslinks of collagen reflect cartilage and bone involvement in rheumatic joint diseases. J Rheumatol 16: 964-970, 1989
32. Slovik RM, Gundberg CM, Neer RM, Lian JB: Clinical evaluation of bone turnover by serum osteocalcin measurements. J Clin Endocrinol Metab 59: 228-230, 1984
33. Stromstedt PE, Berkenstam A, Jornvall H, Gustafsson JA, Carlstedt-Duke J: Radiosequence analysis of thu human progestin receptor charged with [3H]promegestone. A comparison with the glucocorticoid receptor. J Biol Chem 265/22: 12973-12977, 1990
34. Telimaa S, Puolakka J, Rönnberg L, Kauppila A: Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1: 13-23, 1987
35. Woitge HW, Seibel MJ, Ziegler R: Comparison of total and bone specific alkaline phosphatase in skeletal and non-skeletal diseases. Clin. Chem 42: 1796-1804, 1996
36. van Daele PL, Seibel MJ, Burger H, Hofmann A, Grobbee DE, van Leeuwen JP, Birkenhager JC, Pols HA: Case control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. Br Med J 312: 482-483, 1996
37. Waller KG, Shaw RW: Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 59/3: 511-515, 1993